ANI Pharmaceuticals Inc

ANI Pharmaceuticals is a diversified bio-pharmaceutical company that develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses. On September 16, 2024, the company acquired Alimera Sciences, Inc., adding two new products: ILUVIEN® and YUTIQ®. In March 2025, the FDA approved an expanded label for ILUVIEN to include the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS), in addition to its existing indication for Diabetic Macular Edema (DME). The company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. During the second quarter of 2025, the company shifted its U.S. promotional efforts from YUTIQ to ILUVIEN, leveraging its combined label for DME and NIU-PS. The company owns and operates three pharmaceutical manufacturing facilities: two in Baudette, Minnesota, and one in East Windsor, New Jersey. These facilities are capable of producing oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products requiring a fully-contained manufacturing environment. The company ceased operations at a manufacturing facility in Oakville, Ontario, as of March 31, 2023.